Alejandro Sardi-Freitez, MD
Pulmonary Disease · Dover, DENPI 1962610774
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,150 of the $2,843 with a category attached, or 75.6%. Intuitive Surgical accounts for 91.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $1,432 and has fallen 96.7% since, to $48 in 2025.
Across 27 payments — averaging $105.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Veran Medical Technologies, Inc.$92
- AstraZeneca$36
- Boehringer Ingelheim$34
- Johnson & Johnson$34
- GSK$32
- plus $14 from 1 others
What the payments were for
- Travel & lodging$2,15076%
- Food & beverage$69324%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $2,601 |
| Veran Medical Technologies, Inc. | 2 | $92 |
| AstraZeneca | 1 | $36 |
| Boehringer Ingelheim | 1 | $34 |
| Johnson & Johnson | 1 | $34 |
| GSK | 1 | $32 |
| Ambu Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$2,093
How this compares
$2,843 in reported general payments places this provider in the 65th percentile of 39 pulmonary disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $64,844 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,798 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $3,853 |
| Roflumilast | 12 | $2,886 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,831 |
| Azithromycin | 20 | $738 |
| Prednisone | 15 | $253 |
| Methylprednisolone | 17 | $162 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $32 | $73,642100 claims |
| AstraZenecaSymbicort | $36 | $3,85315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 39 pulmonary disease providers in Delaware.
Other pulmonary disease in Dover
- David JawaharDover$9K
- Margarita GianniosisDover$4K
- Brian WalshDover$1K
- Maria AzharDover$0
- Victor BanzonLewes$300K
- Albert RizzoNewark$162K
- Michel SamahaMilford$94K
- Haroon RajaNewark$44K
- Ismael MatusNewark$27K
- Vikas BatraLewes$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.